SGP on Nasdaq

SpyGlass Pharma, Inc.

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerSGP on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersIrvine, California1
  • Incorporated inDE2
  • Business address15326 Alton Parkway, Irvine, Ca 926182
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4-$41.4M in 2025+53% since 2024
-$60.0M-$40.0M-$20.0M02024: -$27.1M-$27.1M20242025: -$41.4M-$41.4M2025+53%
Net income4-$39.9M in 2025+37% since 2024
-$40.0M-$30.0M-$20.0M-$10.0M02024: -$29.2M-$29.2M20242025: -$39.9M-$39.9M2025+37%
Fiscal year2023202420252026
Research and development$20.0M4$29.2M4
Operating expenses$27.1M4$41.4M4
Operating income-$27.1M4-$41.4M4
Income before tax-$29.2M4-$39.9M4
Income tax$04$04
Net income-$29.2M4-$39.9M4
Earnings per share-$16.314-$17.984
Earnings per share (diluted)-$16.314-$17.984
Shares (weighted, basic)1.8M shares42.2M shares4
Shares (weighted, diluted)1.8M shares42.2M shares4

Compare SpyGlass Pharma, Inc. with another company

Leadership

Who has led SpyGlass Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Patrick H. Mooney2026–now

Chief financial officer

  1. Jean-Frederic Viret2026–now

Chief operating officer

  1. James Robert Dennewill Jr.2026–now
Board members and other officers (12)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorBilal Khan named Jun 5, 202519
  • DirectorCynthia Yee named Jul 11, 2023 to Jun 5, 202519
  • DirectorGeoff Pardo named Jun 5, 202519
  • DirectorJake Merrill named Jun 5, 202519
  • DirectorRoger Zhang named Jul 11, 2023 to Jun 5, 202519

Former names

  • SpyGlassPharma, Inc.Jul 11, 2023 to Jun 5, 20252
  • SpyGlass Ophthalmics, Inc.Jun 5, 2019 to Jan 5, 20212

Timeline

  1. Feb 5, 2026New chief executive Patrick H. Mooney becomes CEO7

Filings

89 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 7 major events, 54 insider forms, 6 large holders, 2 private raises, 17 other. The latest 20:

  1. Oct 1, 20268-K EDGAR
  2. Aug 6, 202610-Q EDGAR
  3. Aug 6, 20268-K EDGAR
  4. May 14, 202610-Q EDGAR
  5. May 14, 20268-K EDGAR
  6. Mar 26, 202610-K EDGAR
  7. Mar 26, 20268-K EDGAR
  8. Mar 9, 20268-K EDGAR
  9. Feb 17, 2026SCHEDULE 13G EDGAR
  10. Feb 17, 2026SCHEDULE 13D EDGAR
  11. Feb 13, 2026SCHEDULE 13G EDGAR
  12. Feb 13, 20268-K EDGAR
  13. Feb 13, 2026SCHEDULE 13D EDGAR
  14. Feb 13, 2026SCHEDULE 13D EDGAR
  15. Feb 11, 20264 EDGAR
  16. Feb 11, 20264 EDGAR
  17. Feb 11, 20264 EDGAR
  18. Feb 11, 20264/A EDGAR
  19. Feb 11, 20264 EDGAR
  20. Feb 11, 20264 EDGAR

The 89 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 15 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 9, 2026Khan Bilal ArshadDirectorBuy135,000$16.00$2.2MForm 4
Feb 9, 2026Pardo Geoffrey BDirectorBuy312,500$16.00$5.0MForm 4
Feb 9, 2026RA Capital Healthcare Fund LPDirectorBuy3,690,000$16.00$59.0MForm 4
Feb 9, 2026Behbahani AliDirectorBuy937,500$16.00$15.0MForm 4
Feb 9, 2026Florence Anthony A. Jr.10% ownerBuy937,500$16.00$15.0MForm 4
Feb 9, 2026BASKETT FOREST10% ownerBuy937,500$16.00$15.0MForm 4
Feb 9, 2026NEA 17 GP, LLC10% ownerBuy937,500$16.00$15.0MForm 4
Feb 9, 2026Yang Rick10% ownerBuy937,500$16.00$15.0MForm 4
Feb 9, 2026Makhzoumi Mohamad10% ownerBuy937,500$16.00$15.0MForm 4
Feb 9, 2026SANDELL SCOTT D10% ownerBuy937,500$16.00$15.0MForm 4
Feb 9, 2026Mathers Edward T10% ownerBuy937,500$16.00$15.0MForm 4
Feb 9, 2026Chang Carmen10% ownerBuy937,500$16.00$15.0MForm 4
Feb 9, 2026Walker Paul Edward10% ownerBuy937,500$16.00$15.0MForm 4
Feb 9, 2026Nielsen Kirk G.DirectorBuy165,000$16.00$2.6MForm 4
Feb 9, 2026Vensana Capital I GP, LLC10% ownerBuy165,000$16.00$2.6MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 30, 2025Raised $75 million in a private offering of equity Form D: 10 investors so far Form D
  2. Jul 6, 2023Raised $40 million in a private offering of equity Form D: $90 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 52. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.8,021,117$178.6M1.6%No change
NEA Management Company, LLC7,392,301$164.6M10.4%No change
Sands Capital Alternatives, LLC2,500,012$55.7M9.1%No change
Samsara Biocapital, LLC2,109,953$47.0M3.9%No change
BlackRock, Inc.711,712$15.8M0.0%+566,973
Vestal Point Capital, LP670,000$14.9M0.3%+3,240
Jpmorgan Chase & Co629,739$13.6M0.0%+52,630
Deerfield Management Company, L.P.550,000$12.2M0.2%No change
Millennium Management LLC507,257$11.3M0.0%+38,463
Aberdeen Group plc493,076$11.0M0.0%+272,622
Vanguard Capital Management LLC434,423$9.7M0.0%−390
Geode Capital Management, LLC277,325$6.2M0.0%+150,785
Franklin Resources Inc233,412$5.2M0.0%−66,588
Affinity Asset Advisors, LLC131,586$2.9M0.1%−118,414
State Street Corp117,561$2.6M0.0%+100,311
Charles Schwab Investment Management Inc85,681$1.9M0.0%+26,071
Northern Trust Corp82,451$1.8M0.0%+61,589
Vanguard Portfolio Management LLC75,812$1.7M0.0%+72,132
Vanguard Fiduciary Trust Co68,498$1.5M0.0%+8,716
Alyeska Investment Group, L.P.57,000$1.3M0.0%No change
TD Asset Management Inc47,580$1.1M0.0%No change
Ameriprise Financial Inc45,668$1.0M0.0%+1,191
Alps Advisors Inc33,932$755.3K0.0%New
Bank of New York Mellon Corp23,944$533.0K0.0%New
Virtus Investment Advisers, LLC17,744$395.0K0.1%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25